文献速递中毒与环境急症心脑血管急症

摄入含AB-FUBINACA与ADB-FUBINACA的电子烟液后出现室上性心动过速和急性意识模糊:一例血清药物浓度定量分析病例报告

Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations.
PubMed 文献 · Clin Toxicol (Phila) · 2017-04-10
一句话结论急性中毒时出现不明原因心动过速、意识模糊且常规毒品筛查阴性,作者认为应考虑合成大麻素毒性。

本文报告一例健康24岁男性摄入两滴含AB-FUBINACA和ADB-FUBINACA的电子烟液,30分钟内出现嗜睡、意识模糊、激越、心悸和呕吐。到急诊科时记录到短阵室上性心动过速并自行缓解,床旁尿液免疫分析未检出娱乐性药物,血检示轻度低钾血症。就诊时血清AB-FUBINACA浓度为5.6 ng/mL、ADB-FUBINACA为15.6 ng/mL;经支持治疗22小时后出院。作者认为不明原因快速性心律失常、意识模糊且娱乐性药物筛查阴性时,应将合成大麻素中毒纳入鉴别诊断。

要点

  • 摄入含AB-FUBINACA和ADB-FUBINACA的电子烟液后30分钟内可出现嗜睡、意识模糊、激越、心悸和呕吐。
  • 到急诊科时可记录到短阵室上性心动过速,该例自行缓解。
  • 床旁尿液免疫分析未检出娱乐性药物,不能据此排除合成大麻素暴露。
  • 就诊时血清AB-FUBINACA为5.6 ng/mL、ADB-FUBINACA为15.6 ng/mL,高于既往报告的致死病例浓度。
  • 作者认为急性中毒出现不明原因快速性心律失常、意识模糊且毒品筛查阴性时,应考虑合成大麻素毒性。

适用人群与场景

  • 摄入含AB-FUBINACA和ADB-FUBINACA电子烟液后出现中毒表现的患者。

处置流程与药物剂量

  • 本例采用支持治疗,患者22小时后出院。

红旗征与不能漏的情况

  • 摄入后30分钟内出现嗜睡、意识模糊、激越、心悸和呕吐。
  • 到急诊科时出现短阵室上性心动过速。
  • 床旁尿液免疫分析未检出娱乐性药物,但临床仍高度怀疑中毒。

研究设计与关键结果

  • 病例报告:健康24岁男性摄入两滴含AB-FUBINACA和ADB-FUBINACA的电子烟液,30分钟内出现嗜睡、意识模糊、激越、心悸和呕吐;到急诊科时短阵室上性心动过速自行缓解;床旁尿液免疫分析未检出娱乐性药物;血检示轻度低钾血症;就诊时血清AB-FUBINACA 5.6 ng/mL、ADB-FUBINACA 15.6 ng/mL;支持治疗后22小时出院。
  • 作者认为本例室上性心动过速很可能是AB-FUBINACA和ADB-FUBINACA暴露所致。
  • 本例血清AB-FUBINACA和ADB-FUBINACA浓度高于既往报告的致死病例。

证据类型、等级与局限

  • 病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,急性中毒出现不明原因快速性心律失常、意识模糊且娱乐性药物筛查阴性时,应将合成大麻素中毒纳入鉴别诊断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: AB-FUBINACA and ADB-FUBINACA are structurally similar synthetic cannabinoids with potent CB1 receptor agonistic effects. Very little is known about their pharmacology and toxicology.

OBJECTIVE: To report a case of supraventricular tachycardia and acute confusion after ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA, with quantitative analysis of the serum drug concentrations.

CASE REPORT: A healthy 24-year-old man ingested two drops of e-cigarette fluid which were later found to contain AB-FUBINACA and ADB-FUBINACA. Within 30 min of ingestion, he became somnolent, confused, and agitated, with palpitation and vomiting. On arrival to the emergency department, a short run of supraventricular tachycardia was noted, which resolved spontaneously. Bedside urine immunoassay failed to detect recreational drugs. Laboratory blood tests showed mild hypokalemia. Exposure to AB-FUBINACA and ADB-FUBINACA was confirmed analytically, with serum concentrations of 5.6 ng/mL and 15.6 ng/mL, respectively, in the blood sample collected on presentation. The patient recovered uneventfully with supportive treatment and was discharged 22 h after admission.

DISCUSSION: AB-FUBINACA and ADB-FUBINACA are orally bioavailable with rapid onset of toxicity after ingestion. In this case, supraventricular tachycardia was likely the result of exposure to AB-FUBINACA and ADB-FUBINACA. The serum concentrations of AB-FUBINACA and ADB-FUBINACA were higher than those previously reported in fatal cases.

CONCLUSION: In the context of acute poisoning, the presence of unexplained tachyarrhythmias, confusion, and a negative recreational drug screen should prompt clinicians to consider synthetic cannabinoid toxicity as a differential diagnosis.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Lam RPK, Tang MHY, Leung SC, et al. Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Clin Toxicol (Phila). 2017. PMID: 28393558. doi:10.1080/15563650.2017.1307385

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。